Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07204964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Jul 31, 2026 to Aug 24, 2026
    • Eligibility criteria expanded, about 35 words
    • Site details revised at 4 of 17 sites
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 960 to confirmed 971
    • Primary and study completion dates: Sep 17, 2026 to Jul 31, 2026
    • Site details revised at 17 of 17 sites
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 17
    • Primary and study completion dates: Sep 18, 2026 to Sep 17, 2026
    • Start date changed from estimate of Oct 10, 2025 to Oct 7, 2025
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.
Trial Details
NCT Number NCT07204964
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Influenza, Human
Related terms Infections, Influenza, Human, Virus Diseases
Enrollment 971 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov